Dalbavancin is the preferred lipoglycopeptide in the outpatient or ED setting.
KIMYRSA: Restricted to use by infectious disease physicians for (1) outpatient administration when dalbavancin (DALVANCE) is not a viable option or (2) used inpatient as a patient’s own med/patient assistance program.
If ordered for an inpatient by an infectious disease specialist in an attempt to expedite discharge, may be used with proper administrative approval (contact a member of AMT). If after-hours or weekend, please send patient name, FIN, and ID provider ordering the medication to HHRxAMT@hhsys.org.
ORBACTIV: Non-formulary, not stocked. An automatic interchange from ORBACTIV to KIMYRSA on 1:1 dosing ratio was approved.
Add Formweb to your mobile device
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Dalbavancin is the preferred lipoglycopeptide in the outpatient or ED setting.
KIMYRSA: Restricted to use by infectious disease physicians for (1) outpatient administration when dalbavancin (DALVANCE) is not a viable option or (2) used inpatient as a patient’s own med/patient assistance program.
If ordered for an inpatient by an infectious disease specialist in an attempt to expedite discharge, may be used with proper administrative approval (contact a member of AMT).
If after-hours or weekend, please send patient name, FIN, and ID provider ordering the medication to HHRxAMT@hhsys.org.
ORBACTIV: Non-formulary, not stocked. An automatic interchange from ORBACTIV to KIMYRSA on 1:1 dosing ratio was approved.
Reviewed: 27 January 2015 (Orbactiv), August 2022 (KIMYRSA)
Updated: November 2021